European biotech funding: “We need to be more bullish, bolder, and faster”
Europe’s biotechnology sector sits at a crossroads. Many companies struggle to scale, secure capital, and compete with ecosystems in the United States and Asia. These challenges were at the center of a recent seminar hosted by EuropaBio, where policymakers and founders discussed the realities of funding biotech companies in Europe.










